Jiangsu Atom Bioscience & Pharmaceutical Co. Ltd. (Atom Bioscience) was established in 2012. The leadership team primarily originates from the United States and possesses extensive expertise in the pharmaceutical sector. Atom Bioscience is a pharmaceutical company focused on research, involved in the discovery and development of new drugs for the treatment of metabolic diseases and cancers. One of Atom Bioscience's multiple pipelines, ABP-671, a unique compound for gout treatment, has successfully finished Phase I clinical trials in the United States and is currently undergoing Phase II clinical trials in Australia.
Jiangsu Atom Bioscience & Pharmaceutical
Headquarters
People's Republic of China